Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines

被引:10
|
作者
Naeem, Doaa [1 ]
Alshamrani, Majed A. [1 ]
Aseeri, Mohammed A. [1 ]
Khan, Mansoor A. [1 ]
机构
[1] King Saud Bin Abdul Aziz Univ Hlth Sci, Pharmaceut Care Dept, Minist Natl Guard Hlth Affairs, King Abdul Aziz Med City, King, WI, Saudi Arabia
来源
PHARMACY | 2018年 / 6卷 / 03期
关键词
empiric; antibiotics; febrile; neutropenia; compliance;
D O I
10.3390/pharmacy6030083
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Febrile neutropenia (FN) is an oncologic emergency which should be treated immediately with empiric antibiotics. Different institutions observe different antibiograms and use different FN management guidelines. Our center implemented FN management guidelines for adult cancer patients in 2009. Hence, we decided to assess compliance with FN management guidelines and to describe the pattern of bacterial infections. Method: We conducted a cross-sectional study on all adult cancer patients admitted with FN. Data were collected from electronic medical records between January and December 2014. Results: One hundred FN episodes met the study inclusion criteria. The mean age of the patients was 41 +/- 17 years; 52% (52 patients) were women. The most common diagnosis was lymphoma (33%). In terms of compliance to institutional FN guidelines, 55% of patients received guideline non-compliant treatment. The most common non-compliant treatment was incorrect amikacin dosing in 31% of patients, followed by incorrect vancomycin dosing in 20%, incorrect piperacillin/tazobactam dosing in 19%, inappropriate use of carbapenems in 18%, and non-compliant vancomycin use in 12% of patients. Bacterial isolates were only observed in 19% of the FN episodes. Among these 19 episodes of FN, Gram-negative pathogens were predominant and were identified in 74% of the episodes, followed by Gram-positive pathogens in 16% and polymicrobial pathogens in 10%. The mean time to defervescence was 2.21 +/- 2 days. Conclusion: Our study concluded that there was a high percentage of non-compliance with our institutional FN management guidelines. We recommend following appropriate empiric antibiotic doses and indications as per institutional guidelines.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Ceftriaxone in febrile neutropenia
    Karthaus, M
    Cornely, OA
    JOURNAL OF CHEMOTHERAPY, 2003, 15 (03) : 211 - 219
  • [42] The cost of a febrile neutropenia
    Lucioni, C.
    Crippa, L.
    Leoncini, O.
    Martinelli, G.
    Mazzi, S.
    Santoro, A.
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (01) : 21 - 24
  • [43] Febrile Neutropenia in an Infant
    Unis, Graham D.
    Carlson, John C.
    Warrier, Rajasekharan P.
    CLINICAL PEDIATRICS, 2019, 58 (07) : 828 - 830
  • [44] FEBRILE NEUTROPENIA: A RETROSPECTIVE AUDIT ON DOOR-TO-ANTIBIOTIC TIME AND ADHERENCE TO FEBRILE NEUTROPENIA GUIDELINES AT A REGIONAL VICTORIAN HOSPITAL
    Siow, Z. R.
    Wong, Z. W.
    Bui, J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 69 - 69
  • [45] Timely administration of antibiotics in febrile neutropenia per updated ASCO/IDSA guidelines.
    Ghimire, Krishna Bilas
    Lin, Po-Hung
    Khan, Irum
    Cadman, Kasandra
    Valero, LeeAnn
    Golick, Janet
    Walker, Maria
    Knightly, Eileen
    Windhorst, Jennifer
    Owens, Jovonne
    Fleming, Patrick Joseph
    Cuellar, Sandra
    Crawford, John
    Feldman, Lawrence Eric
    Venepalli, Neeta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [46] Multinational cooperation in trials and guidelines dealing with febrile neutropenia
    Feld, R
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (02) : 185 - 187
  • [48] Mucositis: from febrile neutropenia to febrile mucositis
    Blijlevens, Nicole M. A.
    Logan, Richard M.
    Netea, Mihai G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 : I36 - I40
  • [49] Management of febrile neutropenia: ESMO Clinical Practice Guidelines
    de Naurois, J.
    Novitzky-Basso, I.
    Gill, M. J.
    Marti, F. Marti
    Cullen, M. H.
    Roila, F.
    ANNALS OF ONCOLOGY, 2010, 21 : v252 - v256
  • [50] Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: authors' response
    Horita, N.
    Shibata, Y.
    Watanabe, H.
    Namkoong, H.
    Kaneko, T.
    CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (03) : 325 - 325